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Abstract
Precision Medicine has become a common label for data-intensive and patient-driven biomedical research. Its intended future 
is reflected in endeavours such as the Precision Medicine Initiative in the USA. This article addresses the question whether it 
is possible to discern a new ‘medical cosmology’ in Precision Medicine, a concept that was developed by Nicholas Jewson 
to describe comprehensive transformations involving various dimensions of biomedical knowledge and practice, such as 
vocabularies, the roles of patients and physicians and the conceptualisation of disease. Subsequently, I will elaborate my 
assessment of the features of Precision Medicine with the help of Michel Foucault, by exploring how precision medicine 
involves a transformation along three axes: the axis of biomedical knowledge, of biomedical power and of the patient as a 
self. Patients are encouraged to become the managers of their own health status, while the medical domain is reframed as 
a data-sharing community, characterised by changing power relationships between providers and patients, producers and 
consumers. While the emerging Precision Medicine cosmology may surpass existing knowledge frameworks; it obscures 
previous traditions and reduces research-subjects to mere data. This in turn, means that the individual is both subjected to 
the neoliberal demand to share personal information, and at the same time has acquired the positive ‘right’ to become a 
member of the data-sharing community. The subject has to constantly negotiate the meaning of his or her data, which can 
either enable self-expression, or function as a commanding Superego.
Keywords Precision medicine · Medical cosmology · Foucault · Big data · Participatory medicine · ’All-of-Us’ research 
program
Introduction
Since October 2016, The Precision Medicine Initiative has 
been re-labelled as the ‘All of Us’ research program (AoU). 
The collection of data from more than a million Americans, 
coming from medical files and biological samples, but also 
from smartphones and other personal devices, allegedly 
offers researchers new insights in the onset of disease. The 
AoU program is part of a bigger trend where biomedical 
research increases its technological capacity through the use 
of Big Data, while at the same time incentives are developed 
inviting citizens to become part of this ‘sharing’ community. 
Both the focus on big data and the emphasis on ‘participa-
tory’ medicine (framing participants as research partners, 
providing mobile health data) reflect new features currently 
arising in the biomedical domain.
In this paper I will address the question whether this con-
stellation of individualised healthcare and big data within 
precision medicine (exemplified by the AoU program) can 
be regarded as a new biomedical paradigm, or even a new 
cosmology, a concept introduced by Nicholas Jewson in 1976 
and explained in more detail below. To address this overall 
question, I will first of all analyse the AoU design as an archi-
tecture reflecting the promising future of ‘Precision Medicine’. 
Precision Medicine is the common label currently in use for 
biomedical research that focuses on data streams, a significant 
amount of which is freely shared between individuals. But the 
terminology is still evolving, so that besides ‘precision medi-
cine’ also ‘personalized medicine’, ‘pharmacogenomics’ and 
‘P4 medicine’ (preventative, predictive, participatory, and per-
sonalized) capture various aspects of the current biomedical 
research climate. These conceptualisations all seem to move 
in the same direction, thus setting the stage for what will be 
referred to here as precision medicine. Various scholars have 
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already contributed to explaining the context and meaning of 
Precision Medicine and I will notably build on the work of 
(amongst others) Boenink and Vogt (Boenink 2009; Vogt et al. 
2016a, b). In this paper I will argue, following Boenink, that 
‘precision’ captures the ambitions and hopes that come with 
this new data-driven and participatory turn, although ‘strati-
fied’ (rather than ‘individualized’) medicine would convey a 
more realistic outcome. In other words, ‘precision’ rather than 
‘individualisation’ seems the overarching concept.
Secondly, Precision Medicine will be assessed against the 
backdrop of a longer history of biomedical constellations, as 
analysed by Michel Foucault and others. Building on these 
previous endeavours, I will try to understand the present by 
assessing it against the backdrop of a broader temporal hori-
zon. Therefore, I will present a concise archaeology of previ-
ous conceptual frameworks that have emerged since the dawn 
of modern medicine, building on the work of Jewson (1976) 
and his followers (Armstrong 1995; Nettleton 2004) as well 
as on Foucault. Jewson refers to these consecutive conceptual 
constellations or frameworks as ‘cosmologies’ and describes 
them as worlds of practices and discourses, each with a par-
ticular profile of its own. In his seminal publication, Jewson 
distinguished three cosmologies, namely Bedside Medicine, 
Hospital Medicine and Laboratory Medicine. Additional cos-
mologies, namely Surveillance Medicine and E-scaped Medi-
cine, were later added by Armstrong and Nettleton respec-
tively. These earlier cosmological profiles will allow me to 
determine the basic features of ‘precision medicine’ as the 
most recent cosmology. Notably, they allow me to assess the 
techno-scientific ideals reflected by the AoU program, as key 
features of precision medicine as such.
I will draw on the work of Foucault, notably by emphasis-
ing three dimensions of the precision medicine cosmology; 
‘Knowledge’, ‘power’ and ‘self’ (Foucault 1984; cf.; Zwart 
2005, 2016a). The first dimension (the knowledge axis) 
focusses on the epistemological developments and allows me 
to discuss some potential benefits and weaknesses of big data.
(Leonelli 2014). As for the power dimension, I will analyse 
and assess how power is redistributed when bioinformatics 
opens up the domain to various commercial actors (Swan 
2009; Zwart 2016b). As to the third axis, the technologies of 
Self, I will address the focus on wellness and the language 
of empowerment that accompanies participatory medicine. I 
will conclude that the debate surrounding precision medicine 
should address the tensions entailed in collecting, processing 
and interpreting large-scale (‘big’) health data.
A new window for viewing health
The Precision Medicine Initiative (PMI) was launched by 
the Obama Administration in 2015 together with a pub-
lication of the Precision Medicine Cohort Program by 
Francis Collins and Harold Varmus in the New England 
Journal of Medicine (Collins and Varmus 2015; Hampel 
et al. 2017). Subsequently, what started as the PMI was 
translated into the All-of-Us cohort study (AoU). In order 
to study the AoU design I have analysed the official docu-
ments on the NIH government website, such as ‘Precision 
Medicine Initiative (PMI) Working Group Report to the 
Advisory Committee to the Director, NIH’ (PMI Working 
Group 2015). Additionally, I have looked into a number 
of perspective papers (Ashley 2016; Collins and Varmus 
2015; Hamburg and Collins 2010; Mirnezami et al. 2014; 
Peterson et al. 2013). I consider the AoU as the actualisa-
tion (concrete and physical) of the very ideals that inspired 
precision medicine discourse from the outset. Similar 
initiatives such as ‘The precision medicine initiative for 
Alzheimer’s disease’, or the ‘100 k Wellness Project’ have 
been developed (Hampel et al. 2017; Hood and Price 2014; 
Vogt et al. 2016a, b).
Similar initiatives are also mentioned in the 2015 PMI-
working group publication such as the UK Biobank, The 
china Kadoorie Biobank and the Estonian endeavor to link 
a population biobank with national health registries (Chen 
et al. 2011; Leitsalu et al. 2015; PMI Working Group 2015, 
p. 19; Sudlow et al. 2015).
The AoU program focuses on a shift from traditional 
research and drug development towards developing an 
overarching structure that includes big data science, sys-
tems biology, genomic sequencing, blood-based biomark-
ers, integrated disease modelling and P4 medicine (Hampel 
et al. 2017; NIH 2016). The AoU aims to employ the wide-
spread use of mobile devices and social media for encour-
aging healthy behaviours (NIH Gov. link 2016, p. 16). New 
approaches to patient participation and empowerment are 
forged via partnerships with a plethora of patient groups. 
Since October 2016 the cohort is called ‘All-of-Us’. It began 
enrolling participants in 2017 and is expected to reach one 
million volunteers within three to four years. Participating 
individuals play a decisive and active role. Sharing data 
and linking these data to health records is expected to lead 
to “the right drug, at the right dose to the right patient” 
(Collins and Varmus 2015). The ‘precision’ label (instead 
of the ‘personalised medicine’ label) is used to prevent the 
expectation that medication will be synthesized personally 
for individual patients (Ashley 2015; National Academy of 
Sciences (NAS) 2011). Rather, precision medicine is about 
creating subcategories of disease, thus furthering stratifica-
tion (Boenink 2016). But this is seen as a major step for-
ward. For although statistical analysis provides evidence 
for the safety and effectiveness of various FDA-approved 
drugs, in practice only limited numbers of patients respond 
positively to evidence-based treatments. Stratification into 
subcategories could improve these outcomes and, as a result, 
improve treatment while reducing the risks of side-effects.
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Initially, the term ‘personalised medicine’ was used for 
efforts to produce a more individualised understanding of 
health and disease on the basis of genetic profiles, shifting 
from symptom-based to genome-based approaches (National 
Academy of Sciences (NAS) 2011; Prainsack 2015). As 
indicated, the recently launched ‘All of Us’ program prefers 
the ‘precision’ label, but likewise focusses on opportunities 
for developing quantitative, individualised estimates of risk 
for a range of diseases. Several scientific opportunities are 
presented by the NIH for the ‘all of Us’ cohort, (National 
Institutes of Health, n.d.) (PMI Working Group 2015, pp. 
15–18). It is expected to:
(a) Develop ways to measure risk for a range of diseases 
based on environmental exposures, genetic factors and 
interactions between the two.
(b) Identify the causes of individual differences in response 
to commonly used drugs (pharmacogenomics);
(c) Discover biological markers that signal increased or 
decreased risk of developing common diseases;
(d) Use mobile health (mHealth) technologies to correlate 
activity, physiological measures and environmental 
exposures with health outcomes;
(e) Develop new disease classifications and relationships;
(f) Empower study participants with data and information 
to improve their own health;
(g) Create a platform to enable trials of targeted therapies.
According to the official White House document ‘Preci-
sion Medicine Initiative: Data Security Policy Principles 
and Framework’ the types of data used for these PMI activi-
ties could include, but are not limited to, clinical and insur-
ance claims data, surveys and demographic data, genomic 
and other biosample-derived data, and mobile, implantable, 
or other equipment or device data, all of which may be stored 
and processed electronically (The White House 2016).
These PMI data include information about the partici-
pant’s medical history and lifestyle, but participants may 
also be asked to provide physical measurements (blood pres-
sure, height and weight, etc.) at a local enrollment center, or 
donate blood and urine samples (NIH 2018a).
In other words, precision medicine combines population 
research with various forms of molecular mapping, giv-
ing rise to big data. Thus, it is expected to involve vari-
ous transformations on the level of vocabularies and labels 
(taxonomy), but also on the level of roles for patients and 
physicians (increased emphasis on patient responsibility in 
terms of self-monitoring and self-management), eventually 
even changing the way in which medicine is organized.
The AoU Initiative was launched in the midst develop-
ments and discourses on personalized medicine, pharmacog-
enomics, P4 medicine, systems medicine, and developments 
in the field of iPOP for example1 (Chen et al. 2012; Leroy 
et al. 2012; PMI Working Group 2015). It may therefore 
be regarded as exemplary, as it demonstrates how thinking 
about genomics in the aftermath of the Human Genome Pro-
ject (HGP) is translated into a concrete initiative. The ‘All 
of Us’ captures the contemporary conviction that research 
should function at the intersection of lifestyle, environment 
and biological make-up. Recent extensions of the P’s in P4 
medicine by adding a fifth P (‘always taking into account 
a Population perspective’) or even a sixth P (the psycho-
cognitive P) is indicative of the fact that the changes are still 
ongoing; it tells us that something is happening (Anaya et al. 
2016; Kondylakis et al. 2014). The suggestion that we are 
in an ‘epoch of shared decision making’ should be critically 
analyzed however in the context of ‘participatory’ medicine 
(Kondylakis et al. 2014).
Boenink offers an important view on recent developments 
concerning Precision Medicine (Boenink 2016). According 
to Boenink we have taken a turn in the direction of molecular 
medicine that entails a shift towards a focus on ‘biomarkers’ 
rather than genetics and genomics. In her chapter ‘Disease in 
the Era of Genomic and Molecular Medicine’ she considers 
some of the main features of health and disease, focusing 
on the underlying technology. While the HGP encouraged 
‘geneticization’ (Lippman 1991) because the underlying 
view of genetics was monocausal and deterministic in its 
understanding of the relationship between genes and dis-
ease, molecular medicine moved away from such a deter-
ministic view; from genes to genome to multiple -omics. 
As a result of what Zwart called a narcissistic offence—the 
realization that the human genome is not as exceptional as 
was initially expected—biomedicine started to look for more 
complex models of disease (Zwart 2007). Boenink calls this 
approach a ‘cascade model of disease’, which is made possi-
ble by the development of molecular biology and nanotech-
nology; because research can now ‘zoom-in and quantify’ 
what is happening, and secondly through the development 
of biobanks, software and algorithms that serve as a neces-
sary background, providing the context for this quantifica-
tion. Here also, biobanks and bioinformatics usually require 
computation, using clear-cut categories to describe disease 
and health. These developments, pointed out by boenink, 
are mentioned in the 2015 PMI-working group report as 
well, stating that the information technology revolution has 
provided remarkable reductions in the cost of data stor-
age. Meanwhile, the raw cost of DNA-sequencing has been 
reduces nearly 10-million-fold from the time the sequencing 
phase of the Human Genome Project began in 1998 (PMI 
1 iPOP means Integrative Personalized Omics Profile ans is currently 
being developed by prof. Snyder famous for the Snyderlab http://
snyde rlab.stanf ord.edu/.
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Working Group 2015, p. 8). Both the zoom-in and the zoom-
out strategies mediate a ‘quantitative view of disease’, where 
disease has become a deviation of a population mean. The 
goal of biomedical research has therefore become to explore 
normal functioning.
Boenink concludes by pointing out two shifts, in line with 
Leroy Hood’s work (Leroy Hood and Flores 2012), although 
Boenink’s assessment of them is more critical than Hood’s. 
One is that there is no real boundary between health and dis-
ease, the other is that a cascade model enables high precision 
claims concerning prediction and prevention.
Hood offers a personal and promising view on prediction 
within systems medicine and the emergence of P4 medicine 
(Leroy Hood and Flores 2012). Hood envisions to ‘make 
blood a diagnostics window for viewing health and disease 
for the individual’. Another objective is to ‘Generate met-
rics for assessing wellness.’ This view is in accordance with 
what in the AoU is seen as scientific opportunities such as 
discovering biomarkers that identify individuals with an 
increased risk of developing common diseases, but also the 
opportunity to develop new disease classifications and rela-
tionships and promote healthy behavior (p. 15). In response 
to these developments Vogt et al. argue that health and ill-
ness are seen as something concrete, objective and already 
there (Vogt et al. 2016a, b) and they criticize Hood and Flo-
res’ view that disease and wellness can be seen as a con-
tinuum of network states (unique in time and space for each 
individual human being), captured in biometrics. According 
to these authors the concept of complexity is reduced to 
a technoscientific version of holism; although the process 
of life is defined as complex, it is still defined in terms of 
quantifiability, predictability and actionability; and therefore 
appears controllable. Moreover, the authors warn that; ‘it is 
a fallacy to assume that providing a quantitative correlate 
to a construct that is already normatively defined automati-
cally makes it objective, purely scientific or non-normative.’ 
(Vogt et al. 2016a, b, p. 413). Thus, they urge us to be more 
suspicious concerning the technological backdrop of these 
numbers.
In summary, precision medicine is the general idea that 
the more health data we gather, the more we can quantify, 
the more we can control. In consequence, the boundary 
between health and disease becomes obscured. It is sug-
gested that we can intervene at various stages in a variety 
of molecular cascades. On the normative level, precision 
medicine entails the idea that adequate health management 
will allow individuals to increase their chances of remaining 
within the healthy strata of the population.
Theoretical framework: medical cosmology
Before analysing Precision Medicine as a medical cosmol-
ogy, I will first of all describe the methodological and con-
ceptual background of the cosmology approach. In 1976 
Nicholas Jewson described a series of transformations in 
how disease and illness had been conceptualized during 
the previous two centuries. Notably, Jewson pointed out 
that medical knowledge has gradually become increasingly 
abstract and distant, due to changes in the “mode of pro-
duction” of medical knowledge. With each successive step, 
the distance between caregiver and patient, and between 
lab bench and bedside, had increased. Jewson described the 
medical world as a cosmology, a constellation of practices, 
vocabularies, institutional networks, etc. and the general 
trend which he discerned in modern history was a gradual 
“disappearance of the sick man from medical cosmology” 
(Jewson 1976). Rather than in specific practices or specific 
semantical issues, Jewson was interested in outlining the 
cosmology as a whole, the emergence of new constellations 
within the medical domain, involving new physician-patients 
interactions as well as new vocabularies and taxonomies.2
Cosmologies can be seen as a set of axioms and assump-
tion which guide the interests of medical investigators. 
Therefore it is a way of seeing, but also of not seeing. A 
medical cosmology should not be regarded as a static norma-
tive framework, but rather as an evolving set of possibilities 
and impossibilities (inclusions and exclusions). It was Jew-
son’s specific interest to show that medical knowledge entails 
active knowing and is therefore a mode of social interaction. 
The medical cosmology is the medium within and through 
which perceptions of self and others are expressed, legiti-
mized and institutionalized. In summary, medical cosmolo-
gies are not only statements about the world, but enactments 
of ways of relating to others in this world.
The profile of a cosmology is dependent upon a distinc-
tion that is made from the very beginning; a cosmology can 
be structured around either persons or objects. The constella-
tion of meaning assigned to medical events depends on this. 
According to Jewson, person-oriented cosmologies provide 
a wide range of alternatives for the expression and realiza-
tion of meanings, and he speaks of letting each individual 
develop his or her own particular perception of a body-
self. Object-oriented cosmologies function differently. In 
such a cosmology, persons relate to one another in terms 
of the social categories to which they belong, so that they 
are treated as if they were things or objects. Jewson states 
2 In Jewsons 1976 paper a footnote mentions that the notion of cos-
mology bears close resemblance to Althusser’s ‘problematic’, and 
Kuhn’s ‘paradigm’, additionally parallel ideas are to be found in Bor-
dieu’s ‘intellectual field’, Foucault’s ‘discursive formation’.
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‘The study of life is replaced by the study of organic mat-
ter.’ Modern medicine, he argues, is focused upon the recur-
ring, objective, quantitative characteristics of categories of 
the sick rather than upon the unique, subjective, qualitative 
difference between individuals. By knowing how medical 
knowledge is ‘made’, we can learn what these evolving rela-
tions look like.
The term cosmology indicates that Jewson’s objective 
was not to write a history of medicine, but rather to develop 
a typology, a temporal sequence of types or styles of medi-
cal practice, comparable to, for instance, to the paradigm 
concept of Kuhn or the episteme-concept of Foucault. But 
whereas Kuhn’s paradigm concept focusses on science and 
scientific worldviews, Jewson’s cosmologies involve prac-
tical, clinical and ethical aspects as well (Greaves 2002; 
Nicolson 2009). Jewson’s approach is comparable to Fou-
cault’s archaeology, as developed in The Birth of the Clinic 
(Foucault 1963) and other writings. It is not a purely descrip-
tive endeavour, but entails a critical analysis, a critical diag-
nostics, allowing us to assess the epistemological and ethical 
strengths and weaknesses of particular cosmologies. And 
indeed, in his paper on surveillance medicine, discussed 
below, Armstrong (1995) not only introduced a fourth cos-
mology, but also explicitly connected Jewson’s analysis of 
medical cosmologies with Foucault’s analysis of medical 
topologies.
Building on this body of work by Jewson and others, 
the question that will be addressed in this paper is whether 
precision medicine can be represented as a cosmology of 
its own and, if so, how it differs from previous cosmolo-
gies; what are the defining features of Precision Medicine, 
represented as a cosmology? New technologies prepare the 
ground for the emergence of new medical cosmologies, but 
they never fully replace the previous ones. Rather, each 
successive cosmology absorbs specific features of previ-
ous cosmologies, embedding them into new constellations. 
Jewson speaks therefore of an ‘eclipse’ of bedside medi-
cine by hospital medicine and, subsequently, of hospital 
medicine by laboratory medicine. In each medical cos-
mology, biomedical researchers and research subjects are 
positioned in a certain way. Yet, new ways of ‘knowing’ 
reshape these relationships and the positions these actors 
have, relative to the institutions to which they belong. We 
can speak of a new cosmology when new technologies and 
new forms of biomedical knowledge give rise to a reorgan-
isation of the elements or the objects within the existing 
cosmology. As Pickstone phrases it: cosmologies should 
not be seen as successive types of medicine, but rather as 
inter-penetrating types, where novel forms of medicine 
co-exist with the old in contested cumulations (Pickstone 
2009; Tutton 2012).
I will now briefly describe the overall profile and key 
components of these five cosmologies before turning atten-
tion to Precision Medicine. Table 1 offers a concise overview 
of these five profiles. According to Jewson, Bedside Medi-
cine emerged around 1770. In this cosmology, the patient 
was regarded as a totality, a person. Patient and physician 
developed an interpersonal relationship and medical care 
was provided in response to the specific needs and wishes 
of the individual patient (provided he or she was able to pay 
for this type of care).
Hospital Medicine emerged in the early nineteenth cen-
tury, when medicine attempted to develop a more formal 
knowledge structure in order to guide professional prac-
tice. Hospital medicine focused on pathology and accurate 
diagnostics, rather than on care or therapy. The sick person 
became a “collections of organs”, exposed to a scientific 
gaze, an analysis which to some extent concurs with Fou-
cault’s description of the “birth of the clinic” (Foucault 
1963). And indeed, Foucault likewise considers the year 
1800 as an important turning-point.
During the final decades of the nineteenth century, how-
ever, this focus on pathology and diagnostics was signifi-
cantly strengthened by laboratory research, and this resulted 
in the emergence of a third cosmology, namely Laboratory 
Medicine, which again entailed a drastic conceptual and 
practical reframing of health and disease. From now on, with 
the help of X-rays and blood samples for instance, disease 
was located in microscopic events, brought to the fore via 
biomedical technology (Rosenberg 2007, pp. 19–20). Illness 
Table 1  Medical cosmologies
Occupational role of physician Perception of the “sick man” 
(i.e. patient)
Task of biomedical investigator Conceptualisation of illness
Bedside Practitioner Person Prognosis and therapy Overall psycho-somatic 
disturbance
Hospital Clinician Case Diagnosis and classification Organic lesion
Laboratory Scientist Cell complex Analysis and explanation Biochemical process
Surveillance Epidemiologist Risk assemblage Conversion of epidemological 
risk toclinical risk
Latent deviation from norm
E-scaped Information scientist Expert patient health seeker Assessment and communication 
of risk evidence
Communication breakdown
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was transferred as it were from the bedside into the extra-
corporeal laboratory realm.
Building on Jewson’s seminal publication, Armstrong 
(1995) subsequently presents a fourth cosmology, namely 
surveillance medicine, focussed on monitoring the health 
status of populations (rather than individual patients) and 
the distribution of disease within populations. According 
to Armstrong, illness is now redefined in terms of individ-
ual deviations from statistical norms and thus involves ‘a 
problematisation of the normal’. Illness becomes a statisti-
cal phenomenon, describable as the relative position of an 
individual within a population; illness is captured in terms of 
‘risk’ and ‘lifestyle’. This is not only a theoretical reorgani-
sation, for it also affects the organization of medicine, result-
ing in the development of new types of interventions, new 
institutions and a new relation to the self. As was already 
indicated, Armstrong combines the cosmology concept 
developed by Jewson with the topological archaeology of 
Foucault, emphasising that surveillance medicine entails 
a very specific “spatialisation” of disease, a “remapping” 
of illness, reflecting a shift of the medical gaze into extra-
corporal space, a shift of focus from observing hospitalised 
patients to monitoring interactions between individuals in 
seemingly healthy populations.
In addition, a more recent cosmology has been put for-
ward by Nettleton (2004), namely “E-scaped medicine” 
(2003), based on the rise of the internet as a global archive 
of biomedical information and as a means for communica-
tion (i.e. web 1.0, in combination with email and use of 
webfora). Her analysis is inspired by de Mul’s work on 
‘the informatization of the worldview’ (Mul 1999). Due 
to the internet and other infrastructures, she argues, medi-
cal information becomes accessible to broad audiences in 
novel ways. Medical knowledge spreads to multiple virtual 
locations. Lay people (patients and healthy citizens) can 
access the medical domain from anywhere, so that medical 
information becomes de-institutionalized. For Nettleton, the 
informational turn explains a turn towards Evidence-Based 
Medicine as a central organizing concept (in opposition to 
the ‘art of medicine’). Besides changing medical practice, 
this also prepares the ground for problem-based learning in 
university curriculums, and explains why clinical decision-
making increasingly relies on communication and informa-
tion interchange (cf. Nicolson 2009). A focus on analysabil-
ity, programmability and controllability is central to medical 
knowledge within this cosmology rather than ‘mechanical 
medicine’ (Lupton 2012; Nettleton and Burrows 2003).
These cosmologies can be summarised in shorthand in 
the form of the following diagram, a concise version of 
the diagram developed by Nettleton (2004), which was an 
extension of Jewson’s original diagram3 (1976, p. 228). 
Thus, this table summarises a whole body of literature.
Precision medicine as a biomedical 
cosmology of the present
In this section I will address Precision Medicine as an 
emerging medical cosmology. What are the key features of 
precision medicine? As indicated by the headings shown in 
Table 1, a new medical cosmology entails a new conceptu-
alization of disease that not only changes the role and task 
of physicians and biomedical investigators, but also entails 
a new perception of the target of biomedical interventions, 
referred to by Jewson as “the sick man”.4 In terms of the 
cosmology concept, Precision Medicine emerges as a new 
constellation at the intersection of laboratory medicine, 
surveillance medicine and e-scaped medicine, each of them 
contributing some specific conceptual features that are reas-
sembled under the new heading of precision medicine. It 
combines a focus on molecular medicine with the use of 
large-scale population data and a decidedly informational 
orientation.
The following quote for instance indicates the expectation 
that, building on previous forms of knowledge (i.e. cosmolo-
gies), the AoU will develop a new disease classification, 
one that is sensitive to molecular characterization and the 
availability of large data sets;
Current classifications of disease typically group 
symptoms, signs, and laboratory results into a discrete 
diagnostic category. Underlying these structures is a 
disease nomenclature anchored in centuries of obser-
vation prior to the current era of molecular characteri-
zation. A large and complex set of data points from 
one million or more participants, including compre-
hensive clinical records, a broad range of laboratory 
and molecular investigations, and clinical diagnoses 
and health outcomes, provides the opportunity to dis-
cover unexpected connections within the data as well 
as new subtypes of disease. (PMI Working Group 
2015, 17)
At the same time it shows that these former cosmologies 
are ‘eclipsed’ by precision medicine, notably by the belief 
3 Jewson and Nettleton speak in terms of patron and patronage as 
well i.e. the economical organization of the relationship. Because this 
paper intends to show a shift in focus in the conceptualization of ill-
ness, and with that a changing role for medical investigator these con-
cepts are left out.
4 For the sake of coherence I decided to stick to the ‘sick-man’ as 
Jewson originally put it although referring to a woman, person or sub-
ject might be more appropriate.
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in big data science. How the PMI envisions the expanding 
wings of Big Data is apparent in the following quote;
The PMI cohort is being launched at a time of explo-
sive growth in the number, size, and complexity of 
potentially relevant data resources. The “big data” of 
human biology, such as full genomes and high resolu-
tion digital images, may be combined with other novel 
forms of equally large or larger data, such as weather 
patterns, environmental monitoring, and streaming 
physiologic sensor data from study participants. P. 67
Through the combination of data as such, these former 
cosmologies converge [or cumulate (Pickstone 2009)] into 
Precision Medicine as a new constellation, a new combina-
tion of continuity and discontinuity, of existing and innova-
tive features. As indicated earlier, Precision Medicine and 
its focus on biomarkers foresee opportunities for interven-
tion and prediction, and ultimately self-management through 
mobile health devices. This will allegedly enable a whole 
new set of unexpected assosciations, as is reflected in the 
following quote;
The PMI cohort will provide a broadly useful resource 
for rigorously validating and quantifying the contri-
butions of genetic and environmental risk factors, as 
well as their interactions with one another, in a large, 
diverse population. This will certainly include risk 
factors that have been proposed from smaller studies, 
but the comprehensiveness of the PMI cohort dataset 
will also allow for data scientists to identify new and 
unexpected associations. As it grows in breadth and 
depth, the PMI cohort will allow for these estimates on 
uncommon as well as common diseases. p. 15.
These claims and promises allow a reconceptualiza-
tion of the categories of Table 1, expressed in Table 2. The 
emerging cosmology implies a new role for physicians and 
patients, for both are now involved in the collection and pro-
cessing of enormous amounts of data. While doctors have to 
interpret health data and consult their patients, patients are 
actively taking up mobile health and self-monitoring prac-
tices in order to improve their health and participate in the 
research process (PMI Working Group 2015, pp. 62, 63) 
Although ultimately it is the professional’s job to suggest 
biomarker-based behavioural change (in terms of life-style, 
diet, medication etc.), individuals themselves are to decide 
what technology to purchase and which data to process, ulti-
mately rephrasing the subject in terms of digital consump-
tion, staging them as digital consumers. In the AoU this is 
captured by a vision that participants become ‘partners’ in 
managing their health.
A goal of the PMI cohort is to empower individuals 
to understand potential opportunities to manage their 
health offered through genomic sequencing, aggrega-
tion of longitudinal health information, and sharing of 
data with researchers, under a cooperative model of 
partnership and trust. (PMI Working Group 2015, 40).
This goal (to empower individuals as active consumers) is 
even more explicitly expressed in the AoU’s objective to use 
mobile health technology and wearables. One example is the 
Fitbit pilot that was announced by Director of the AoU pro-
gram Eric Dishman, who actively seeks an audience within 
the AoU ‘community’ with the help of YouTube videos and 
explains his interest to use data from the devices that the 
participants are already using. (Dishman 2017). The pilot 
involves an interest in how to pull fitbit-data; Fitbit is a com-
pany famous for its activity trackers based on wearable tech-
nology that measure data such as number of steps, heartrate, 
sleeppatterns etc. The information is individual-based, but in 
order to assess the meaning of this individualised informa-
tion, it has to be connected with large-scale data reposito-
ries. In other words, although precision medicine claims to 
bring the individual body back into view, the patient’s body 
actually emerges against the backdrop of data derived from 
millions of other individuals. The biomedical gaze reverts 
from the population back to the individual body, but this 
Table 2  Medical cosmologies; precision medicine
Cosmology Occupational role of physician Perception of 
‘sick man’ (i.e. 
patient)
Task of biomedical investigator Conceptualization of Illness
Bedside Practitioner Person Prognosis and therapy Overall psycho-somatic disturbance
Hospital Clinician Case Diagnosis and classification Organic lesion
Laboratory Scientist Cell Complex Analysis and explanation Biochemical process
Surveillance Epidemiologist Risk assemblage Convert epidemiological risk to clinical 
risk
Latent deviation from norm
E-scaped Information scientist Expert Patient
Health Seekers
Assessment and communication of 
risks; and assessment of research 
evidence
Communications breakdown, inter-
action of systems
Precision Data-consultant Digital consumer Biomarker based health promotion Ill-managed molecular cascades
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body now emerges as a database, a valuable and exploit-
able resource of information. Jewson’s “sick man” has been 
replaced by consumers of digital information, as was already 
articulated by Barack Obama, for instance, when he claimed 
that each household should be able to access their health 
data (Obama 2015). Table 2 contains an updated version of 
Table 1, adding a row for Precision Medicine regarded as a 
medical cosmology.
Foucault
In Foucault’s oeuvre, three dimensions or axes of inquiry 
can be distinguished, namely knowledge, power and the Self 
(Foucault 1984; Zwart 2005, 2016a). These axes are exem-
plified by key publications such as, ‘Words and things’ (Fou-
cault 1966), ‘Discipline and Punish’ (Foucault 1975) and 
‘The care of the self’ (Foucault 1984) respectively. Zwart 
(2005, 2016a) has argued that these axes can be used as 
windows into contemporary technoscience as a new epis-
temic formation, allowing us to ask three types of questions, 
namely questions concerning (a) new practices of knowl-
edge, (b) new practices of power and (c) new practices of the 
Self enabled by contemporary technoscience (Zwart 2005). 
In this section, I will use these three axes (these three sets 
of questions) to extend my cosmological analysis of preci-
sion medicine.
The relevance of Foucault’s work for cosmology analysis 
was already recognised by others. In his work on surveil-
lance medicine, Armstrong already pointed to the affinities 
between the approaches of Jewson and Foucault. Armstrong 
showed that a focus on risk and lifestyles entailed a recon-
figuration of symptoms, signs and illnesses, opening up 
new space of future understandings of health and disease. 
Medicine is increasingly enacted in an extracorporeal space, 
represented by the notion of lifestyle. This gives rise to a 
new spatialiation; a remapping of illness outside the organic 
confines of the body. This claim is grounded in Foucault’s 
observation that a new “epistemic formation” or “episteme” 
will involve new organisations of space and time, new forms 
of spatialisation and temporalisation. In the context of preci-
sion medicine, key terms such as risk and lifestyle are rede-
fined and absorbed into a new cosmology. Notably, they are 
defined in terms of massive data streams and fine-grained, 
highly detailed molecular information.
Thus, in order to deepen our understanding of this par-
ticular cosmology, three types of questions must be asked. 
Concerning the epistemological dimension: what new forms 
of knowledge are produced? Concerning the bio-political 
dimension: how does this affect power relationships? And 
finally, concerning the ethical dimension: what new prac-
tices of the self are allowed to evolve in response to the new 
knowledge-power constellation?
The knowledge dimension: the big data 
of human biology
The emerging Precision Medicine cosmology entails a 
remapping of illness in large data repositories. Ongo-
ing monitoring and collection of data provides a detailed 
perspective on illness where inner and outer, body and 
environment are constantly connected. These new forms 
of spatialisation and temporalisation gives rise to new 
knowledge practices.
The PMI Working Group foresees several sources of 
research data needed to support the scientific opportu-
nities pursued in the cohort: individual demographics 
and contact information, terms of consent, self-reported 
measures, behavioural and lifestyle measures, sensor-
based observations, clinical data (from electronic health 
records), baseline health exam, healthcare claims data, 
research specific observations, bio-specimen derived 
laboratory data, geospatial and environmental data and 
lastly ‘other data’, ranging from social networking data 
to medication purchases (PMI Working Group 2015, pp. 
47–48). In the AoU biomedical data are thus procured 
from various sources; the molecular or microscopic level 
is represented by the –omics world (genomics, proteom-
ics, metabolomics, lipodomics, transcriptomics, epigenet-
ics, microbiomics, fluxomics, phenomics, etc.), while the 
macroscopic or ecological world involves epidemiological 
data of populations and public health informatics (Hampel 
et al. 2017; Holzinger et al. 2014; Hood and Price 2014). 
Big Data therefore gains enormous importance because it 
generates data-driven insights on a systemic level, bring-
ing these different sources together (Holzinger et al. 2014). 
Big Data science becomes the epistemic base of precision 
medicine as such.
Big Data analytics generate insights that are “born from 
the data” (Kitchin 2014). Chris Anderson, editor-in-chief 
of Wired magazine, calls the use of Big Data the end of 
theory: “Forget taxonomy, ontology, and psychology. Who 
knows why people do what they do? The point is they do 
it, and we can track and measure it with unprecedented 
fidelity. With enough data, the numbers speak for them-
selves” (Anderson 2008). Big data can be summarized in 
terms of three major shifts. First of all: Big Data means 
N = all. Secondly, N = all means that data can be procured 
from many different resources. And finally, Big Data 
implies a shift from causality to correlations (Sax 2016). 
Because of these shifts, Big data provides new types 
of ‘explananda’: it shows the what rather than the why 
(Anderson 2008; Mayer-Schonberger and Cukier 2013; 
Sax 2016). Instead of providing answers to questions, it 
provides answers, and we should search for the right ques-
tions to ask. The main concern is how to translate all these 
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answers into useful knowledge. For the AoU this means 
that their attempt to gather such a database involves a flood 
stream of correlation-based information still in need of 
explanatory power. In many ways it means handing over 
knowledge-making practices to algorithms and computer 
intelligence in unprecedented ways.
Kitchin describes several beliefs that underlie big data, 
such as the idea that big data research doesn’t have to rely 
on an a priori theory, that data are free of human bias and 
that, in the case of data, meaning transcends context (Kitchin 
2014). Kitchin problematizes these beliefs, arguing that (big) 
data do not arise from nowhere, and are never free from the 
“regulating force of philosophy” (Berry 2011, p. 8; Kitchin 
2014). He points out that inductive strategies for identify-
ing patterns in data do not occur in a scientific vacuum but 
are discursively framed, building on previous experiences 
and established knowledge (Kitchin 2014; Leonelli 2012). 
This implicit philosophy of big data science obscures former 
medical cosmologies, those which continue to pass on tra-
ditional tools and styles of thinking to the present situation.
Leonelli questions the epistemological ideals presented 
by Mayer-Schonberger and Cukier in their book Big Data 
(Leonelli 2014). According to Leonelli, an important epis-
temic weakness of big data is that it tends to be “lossy”. This 
term, coined by Mayer-Schönberger and Cukier, explains 
that the sheer quantity of data compensates for certain lev-
els of inexactitude (Mayer-Schonberger and Cukier 2013, 
p. 200). According to these authors, accuracy becomes 
less important in view of the volume of the information 
processed, so that specific forms of incorrectness will be 
levelled-out. Big numbers do not need to meet the same 
requirements that are mandatory in traditional research. 
However, Leonelli argues that the various social, political, 
economic and technical factors that determine which data 
are allowed to be processed are non-transparent and difficult 
to reconstruct by biomedical researchers at the receiving 
end (Leonelli 2014). With Big Data being ‘lossy’, and the 
nontransparant factors that determine which data are allowed 
in, the AoU design might encounter difficulties in trying to 
live up to the expectations entailed in the label ‘precision’ 
knowledge. In any event, precision medicine aims to capture 
the ‘whole domain’ and to collate every quantifiable aspect 
of an individual’s well-being.
The design of the AoU cohort suggests that the truth 
about our lives and bodies is mirrored by the data. This 
involves a new spatialization. Precision medicine creates a 
new type of space where our views of health and disease 
become constructed, namely in the database. But preci-
sion medicine also entails a new form of temporalisation, 
because ongoing real-time monitoring and prediction 
provides constant access to a future situation, resulting in 
new ways of organising the temporal dimension of disease 
processes. Deborah Lupton’s argues that through m-health 
(“mobile health”) technologies, the individual becomes part 
of a flow of information, a continual loop of production of 
health-related data. In a similar fashion the object of Preci-
sion Medicine becomes a digital cyborg body, through the 
constant interaction with technology, i.e. monitoring (Hara-
way 1988; Lupton 2012). Conclusively, framing scientific 
research in terms of big data will yield correlation-based 
hypotheses. On the one hand, a big data focus could point 
to completely new insights that surpass our existing frame-
works, but on the other hand relying on databases as such 
obscures previous traditions and obliterates research subjects 
by replacing them with mere data (Zwart 2016b).
Technologies of power; the digital consumer
Foucault in the 1970s showed a growing interest of govern-
ments into the health conditions of their populations, leading 
to the emergence of ‘bio-power’. The power of a nations 
depends on the health of its citizens (Zwart 2005, p. 36). 
Disciplines such as statistics or demography are ways to reg-
ister and control behavior, ways to acquire power over ‘bod-
ies’. In Precision Medicine, medical knowledge is gathered 
and produced by powerful institutions, shaping and influenc-
ing the way of life of individuals. The PMI Working Group 
suggested that a new era of healthcare is about to flourish 
and that the AoU can only succeed when individuals become 
actively engaged in medical practice;
Coincident with advancing the science of medicine is 
a changing culture of medical practice and medical 
research that engages individuals as active partners – 
not just as patients or research subjects. We believe the 
combination of a highly engaged population and rich 
biological, health, behavioral, and environmental data 
will usher in a new and more effective era of American 
healthcare.’ (PMI working group 2015, 1)
From a philosophical perspective, the idea to engage indi-
viduals as active partners raises suspicion. The call for part-
nership’ poses the question whether there is really a new role 
for individuals (framed as partners), or whether we should 
rather see it as a strategy for making citizens responsible 
for depositing their data in a digital panopticon, as citizen-
managers of their everyday life; empowered to make the 
‘right’ choices? (Devisch and Vanheule 2015). Patients are 
increasingly framed as consumers of health technologies, 
and the medical domain seems to be moving away from gov-
ernments toward private companies.
The focus on health data in combination with this drive 
to frame individuals as active partners, has significant con-
sequences for the question who will be able to influence the 
medical’ecosystem. The data sharing community envisioned 
by the All of Us program entails an infrastructure for the 
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assemblage of multiple types of biomedical data which will 
be managed by a Data and Research Centre. Access can 
be given to researchers, ranging from community colleges 
up to top healthcare research institutes and industries, but 
also for citizen scientists, who can propose studies using this 
information (NIH 2018b). The AoU design requires new 
forms of collaboration between governmental organizations, 
research institutions and industry (AoU online-‘partners’) 
and this is an important element of the institutional base 
of precision medicine, namely public–private partnerships. 
Google’s Verily for example (formerly known as Google life 
sciences) will play a leading role in the data and research 
centre embedded within the AoU design (Heath n.d.; Lash 
2016; NIH 2016, p. new releases; Philippidis 2016). Simi-
larly, Vibrent, a tech company that specialises in AI and 
machine learning, will fulfil a role as participant technol-
ogy systems centre (NIH 2018b; Vibrent Health n.d.). These 
public–private partnerships imply a distributed form of 
knowledge production where hospitals, research institutes 
and high-tech entrepreneurs have to work together. (Lupton 
2012; Prainsack 2014; Swan 2009). The sharing of informa-
tion generates new distributions of roles for the stakeholders 
involved (Aronson and Rehm 2015; Prainsack 2015).
Mayer-Schönberger and Cukier describe an important 
feature of data called ‘option value’. Rather than being sim-
ply consumed, data stay intact and therefore can be accessed 
and reused over and over again. Databases remain valuable 
or may even increase in value for addressing future ques-
tions. This has been the business model for companies 
such as 23andme. The company 23andMe acquired Patien-
tLikeMe, a promising social health network, and has been 
given the role of ‘participant center’ within the AoU design 
(NIH 2018b). The concern here is to prevent health data 
from becoming capitalized by private industry (Dickenson 
2013). Data can re-inform research questions over and over 
again and by acquiring intellectual property rights and pat-
enting specific algorithms, private parties may increase their 
profit. Therefore, access to the AoU database allows private 
parties to harvest profitable insights.
The rhetoric of patient empowerment is used by power-
ful commercial actors (Prainsack 2014). When commercial 
actors mobilize the rhetoric of citizen science and participa-
tory medicine, Prainsack argues, this means alignment of 
profit orientation and health idealism and this might endanger 
true empowerment. Similarly, Juengst et al. (2012) speak of 
“capitalizing” the open-source ethos and urge their readers that 
they should not assume that patient empowerment always yield 
positive outcomes for patients. Empowerment may function as 
an instrument to create demand, or as a device for compliance, 
or as a way to inflate patients’ responsibilities (Juengst et al. 
2012; Prainsack 2014). Other scholars also suggest that the 
free labor that the customers put in by sharing their health data 
is at odds with not sharing any financial profits with those who 
have provided the data, and that patents often erect barriers to 
research by charging licensing fees (Rimmer 2012).
Although the AoU design might be an attempt to coun-
ter this trend and to take the participation aspect seriously, 
similar risks may nonetheless be involved. Important here 
is that access does not by definition solve the problem, for 
gathering large amounts of data is a powerful draw (Leonelli 
2014). Until now, the ‘finders keepers’- principle is at work 
here, criticized by Sax (2016), which enables outsiders to 
access datasets to dig for ‘gold’, leading to asymmetries and 
injustices. Any party that discovers some sort of correlation 
becomes the owner of that information and may patent a 
particular sequence, for example. In the context of AoU, it 
remains unclear how profits and benefits will be shared with 
participating individuals. Individuals are likely to become an 
exploitable resource, handing off data to external, increas-
ingly powerful parties, while powerful commercial actors 
are actively involved in the AoU design and in shaping par-
ticipants’ ‘lifestyle’ choices.
At the same time, however, new opportunities for research 
have been created which may significantly redistribute 
power roles for patients. Examples of this democratization 
of research could also be seen when PatientsLikeMe first 
started, a social network that relied on quantified self-track-
ing (Swan 2009). Such networks have proven to make clini-
cal trials more efficient. A PatientsLikeMe patient gathered 
250 ALS patients to self-experiment with Lithium (Arnst 
2008; Swan 2009). According to Swan, their co-ownership 
of the health care process and the related issues highlight 
the possible role individuals could have in participatory 
medicine.
Devisch et al. argue that if we want to understand the 
willingness to engage with the medical domain (by shar-
ing health data as in the case of the AoU or via direct-to-
consumer genetic testing as in companies such as 23andMe) 
we should realize that these developments are part of an era 
of ‘medical consumption’ (Devisch and Van Hoyweghen 
2011), so that the neoliberal zeitgeist seems an important 
vector in the development of precision medicine. (Dickenson 
2013; Vogt et al. 2016a, b). In this context we should keep in 
mind that big data favors people who are more digitally con-
nected (Collins 2015). Thus, articulating the power dimen-
sion allows us to decipher a tension between the neolib-
eral demand to share personal information and the positive 
‘right’ to become a member of the AoU community.
Technologies of the self; biomarker‑based 
health promotion
The AoU program picks up on a trend where medical tech-
nologies have become mobile, home-based and consumer-
operated, thus enabling remote monitoring. Growing interest 
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in using iPhones, wearables and in-home devices will allow 
the medical domain to draw near (NIH 2016, p. 8). Individu-
als are empowered to become self-reflective agents, through 
the use of smart mobile devices, but at the same time they 
are more closely monitored than ever by something other 
than themselves. Individual biomedical signatures fos-
ter forms of decision-making that are optimised for your 
personal health status, while continuous sharing of health 
data creates a frame of reference for making such decisions. 
Constant monitoring of health data requires individual to 
become the managers of his own health, but the ‘norm’ of 
healthiness is set by an external expert authority (Harvey 
2009; Zwart 2007). From an ethical perspective, however, 
it can be argued that personalised health data (about per-
sonal susceptibilities and the risks involved in diets, life-
style, career choice, etc.) allow individuals to constitute 
themselves as responsible subjects, empowered to develop 
an evidence-based life-style of their own.
In the 1980s, Foucault became interested in the ways indi-
viduals manage to transform themselves into moral subjects, 
using and developing technologies of the self. Whereas pre-
cision medicine might lead us to assume that the NIH is 
hoarding individual data into a digital panopticon, so that 
healthy behavior can be ‘engineered’, the PMI can also be 
seen as a space where practices of freedom are allowed to 
emerge and where individuals can develop a moral lifestyle 
(Zwart 2005, pp. 37, 39). It enables individuals to address 
the question what kind of life they want to lead. However 
this question should not merely pay attention to the ethical 
dimension as such. Rather we should realize that practices 
of the self emerge in the folds and margins of these power-
regimes, guarded by powerful institutions that shape and 
influence ‘life’. Thus, new subcultures such as the quantified 
self-movement emerge in the interspace defined by the three 
axes. (Sharon and Zandbergen 2016).
While Lupton argues that the web 2.0, the internet of 
things and the use of wearables have made it possible to 
directly tailor and target health messages, and that the use 
of these technologies promote techno-utopian, enhancement 
and healthist discourses (Lupton 2012, 2013), Sharon’s eth-
nographic work, studying the Quantified Self Community, 
offers an entirely different perspective on self-tracking 
(Sharon and Zandbergen 2016) Members of this commu-
nity gather data about themselves through self-tracking 
and share their findings within this community. Sharon’s 
analysis confirms, however, that, within this community, 
self-tracking serves other purposes over and above health-
ism or data fetishism. Self-tracking can, for example, foster 
practices of mindfulness. Self-tracking and investigation 
can serve as a practice of resistance against a social norm, 
or as a communicative and narrative practice: a technology 
of self-expression (Sharon and Zandbergen 2016). Along 
this line of thought, precision medicine may indeed provide 
meaningful new opportunities for probing new practice of 
the self.
In “The Obliteration of Life”, Zwart (2016b) explored the 
emergence of technologies of the Self in the “terabyte” age. 
Human individuality, he argues, is captured in high resolu-
tion precision portrayals, but at the same time lost and dis-
solved in massive data streams. Paradoxically, rather than 
enhancing self-management, personal -omics portrayals give 
rise to a molecularised conscience. They serve as indicators 
of normalcy equipped with increased precision. Increasingly, 
bio-citizens are regarded as valuable repositories of informa-
tion Zwart 2016b). Tracking and sharing molecularised self-
assessments play an important role in managing our health, 
thereby created a digital version of a collective Superego.
Conclusively, the individual participant in the AoU has 
to learn to manoeuvre through a digital landscape composed 
of multiple datasets projected against different time frames 
and lifestyles. This context challenges participants to shape 
what it means to be a member of the AoU community. The 
question is not whether pariticpants are empowered or gov-
erned, for the most probable answer is: both. The drive for 
participation within the AoU can point in both directions.. 
The subject has to constantly negotiate the meaning of his or 
her data, and these data can enhance self-expression while 
at the same time confronting us with a forbidding Superego.
Conclusion
Following Boenink and others I argued that tools for molec-
ular biology and the development of biobanks, software and 
algorithms have provided the opportunity for the AoU cohort 
to flourish. This has lead to a focus on prediction and pre-
vention, providing biomarker-based risk estimates. These 
developments seem to demarcate the cosmological profile of 
Precision Medicine. Considering precision Medicine as an 
emerging cosmology has allowed me to address its possible 
impact for researchers, practitioners and participating citi-
zens. Additionally, Jewson’s concept enables an assessment 
of this emerging cosmology so that we may come to terms 
with several ongoing (practical and conceptual) changes in 
the biomedical domain, in terms of roles, tasks and respon-
sibilities. Cosmologically speaking, Precision Medicine 
cosmology combines data-intensive with patient-driven 
research. Tools, traditions and styles of thinking from former 
cosmologies are absorbed, but appear in a new constellation 
and gain new meaning within the AoU design. Foucault’s 
three axes of inquiry (knowledge, power and self) allowed 
me to critically assess the Precision Medicine cosmology 
and show the tensions that arise when Precision Medicine 
is continued in this direction.
The first tension is an important epistemic paradox. 
Although the collection of large amounts of health data 
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provides new insights, big data practices at the same time 
obscure their theoretical and methodological backdrop. 
Framing scientific research in terms of big data seems to 
focus on correlation-based hypotheses. On the one hand, a 
focus on big data could point to completely new insights that 
surpass our existing frameworks, but on the other hand rely-
ing on large-scale databases may obscure previous traditions 
and reduce research-subjects to mere data.
A second tension concerns the dimension of power, 
namely the idea that the collection of data is a participatory 
process, while at the same time it is a strategy to gather data 
as a tool for health care management. The empowerment-
rethoric is a way to create demand, a device for compliance 
and a way to inflate patient’s responsibilities. In the context 
of the AoU design (but this applies to Precision Medicine 
in general), the patient has become a digital consumer. 
This means that the individual, while being subjected to 
the neoliberal demand to share personal information, has 
acquired the positive ‘right’ to become a member of the AoU 
community.
On the level of self I have argued that Precision Medi-
cine provides a space for self-management by individuals, 
via meaningful self-examination. Nonetheless, an entrepre-
neurial logic may actually undermine embodied and expe-
riential knowledge; because individuals are confronted with 
(or haunted by) expectations and standards derived from big 
data repositories functioning as a molecular or digital voice 
of conscience. The subject has to constantly negotiate the 
meaning of his or her data, which can either enable self-
expression, or function as a commanding Superego.
Precision medicine can be considered as an emerging cos-
mology and the AoU program as an exemplification of this 
cosmology, allowing us to develop a preliminary diagnostics 
of what Precision Medicine entails in terms of epistemo-
logical, societal and ethical challenges. These considerations 
may not only deepen our understanding of precision medi-
cine, but may also inform ethical and policy agendas. The 
next step is to address these issues in the public arena and 
to initiate deliberations on how to shape and navigate the 
political ecosystem of precision medicine.
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